Increased Risk of Ischemic Heart Disease in Young Patients with Newly Diagnosed Ankylosing Spondylitis - A Population-Based Longitudinal Follow-Up Study

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Huang, Ya Ping ^a   Wang, Yen Ho ^a,b   Pan, Shin Liang ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMBULATORY CARE; ANKYLOSING SPONDYLITIS; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POPULATION RESEARCH; RISK ASSESSMENT; ADOLESCENT; INCIDENCE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; BRAIN ISCHEMIA; FEMALE; HUMANS; MIDDLE AGED; RISK FACTORS; STROKE; TAIWAN; UTERINE CERVICAL NEOPLASMS; ADOLESCENT; FOLLOW-UP STUDIES; INCIDENCE; LONGITUDINAL STUDIES; MALE; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84877741473     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064155     Document Type: Article

References (41)

1. Braun J, Sieper J, (2007) Ankylosing spondylitis. Lancet 369: 1379-1390.
2. Gran JT, Husby G, Hordvik M (1985) Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 44: 359-367.
3. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J, (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23: 61-66.
4. Bakland G, Nossent HC, Gran JT, (2005) Incidence and prevalence of ankylosing spondylitis in Northern Norway. Arthritis Rheum 53: 850-855.
5. Sukenik S, Pras A, Buskila D, Katz A, Snir Y, et al. (1987) Cardiovascular manifestations of ankylosing spondylitis. Clin Rheumatol 6: 588-592.
6. Lautermann D, Braun J, (2002) Ankylosing spondylitis-cardiac manifestations. Clin Exp Rheumatol 20: S11-15.
7. Roman MJ, Salmon JE, (2007) Cardiovascular Manifestations of Rheumatologic Diseases. Circulation 116: 2346-2355.
8. Divecha H, Sattar N, Rumley A, Cherry L, Lowe GD, et al. (2005) Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci 109: 171-176.
9. Lehtinen K, (1993) Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52: 174-176.
10. Symmons DP, Goodson NJ, Cook MN, Watson DJ, (2004) Men with ankylosing spondylitis have an increased risk of myocardial infarction Arthritis Rheum. 50Suppl: S477.
11. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, et al. (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33: 2167-2172.
12. Peters MJ, Visman I, Nielen MM, Van Dillen N, Verheij RA, et al. (2010) Ankylosing spondylitis: a risk factor for myocardial infarction?. Ann Rheum Dis 69: 579-581.
13. Bremander A, Petersson IF, Bergman S, Englund M, (2011) Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 63: 550-556.
14. Szabo SM, Levy AR, Rao SR, Kirbach SE, Lacaille D, et al. (2011) Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 63: 3294-3304.
15. Zöller B, Li X, Sundquist J, Sundquist K, (2012) Risk of Subsequent Coronary Heart Disease in Patients Hospitalized for Immune-Mediated Diseases: A Nationwide Follow-Up Study from Sweden. PLoS ONE 7: e33442.
16. Mathieu S, Gossec L, Dougados M, Soubrier M, (2011) Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63: 557-563.
17. Brophy S, Cooksey R, Atkinson M, Zhou SM, Husain MJ, et al. (2012) No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis-a retrospective cohort study using routine data. Semin Arthritis Rheum 42: 140-145.
18. Grundtman C, Hollan I, Forre OT, Saatvedt K, Mikkelsen K, et al. (2010) Cardiovascular disease in patients with inflammatory rheumatic disease is associated with up-regulation of markers of inflammation in cardiac microvessels and cardiomyocytes. Arthritis Rheum 62: 667-673.
19. Mathieu S, Motreff P, Soubrier M, (2010) Spondyloarthropathies: an independent cardiovascular risk factor? Joint Bone Spine 77: 542-545.
20. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Dierssen T, Vaqueiro I, et al. (2009) The High Prevalence of Subclinical Atherosclerosis in Patients With Ankylosing Spondylitis Without Clinically Evident Cardiovascular Disease. Medicine 88: 358-365.
21. Peters MJ, van Eijk IC, Smulders YM, Serne E, Dijkmans BA, et al. (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37: 161-166.
22. Bodnar N, Kerekes G, Seres I, Paragh G, Kappelmayer J, et al. (2011) Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 38: 723-729.
23. Caliskan M, Erdogan D, Gullu H, Yilmaz S, Gursoy Y, et al. (2008) Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 196: 306-312.
24. Hamdi W, Chelli Bouaziz M, Zouch I, Ghannouchi MM, Haouel M, et al. (2012) Assessment of preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 39: 322-326.
25. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, et al. (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38: 499-505.
26. Lange U, Teichmann J, Stracke H, (2000) Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 5: 507-511.
27. Ross R, (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
28. Libby P, (2002) Inflammation in atherosclerosis. Nature 420: 868-874.
29. Libby P, Ridker PM, Maseri A, (2002) Inflammation and atherosclerosis. Circulation 105: 1135-1143.
30. Hansson GK, (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695.
31. Ridker PM, Hennekens CH, Buring JE, Rifai N, (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843.
32. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR, (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565.
33. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499-511.
34. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT, (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34: 585-592.
35. Chou CT, Chen JM, Hsu CM, Chen SJ, (2003) HLA-B27 and its subtypes in 4 Taiwanese Aborigine tribes: a comparison to Han Chinese patients with ankylosing spondylitis. J Rheumatol 30: 321-325.
36. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, et al. (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65: 442-452.
37. van den Berg R, Baraliakos X, Braun J, van der Heijde D (2012) First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Rheumatology (Oxford).
38. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302-1308.
39. Hermann M, Ruschitzka F, (2007) Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs. Ann Med 39: 18-27.
40. Cheng CL, Kao-Yang YH, Lin SJ, Lee CH, Lai ML, (2011) Validation of the national health insurance research database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 20: 236-242.
41. Wu CH, Wang YH, Huang YP, Pan SL, (2012) Does Adhesive Capsulitis of the Shoulder Increase the Risk of Stroke? A Population-Based Propensity Score-Matched Follow-Up Study. PLoS ONE 7: e49343.